News
Lymphoma Research Foundation Update on Vincristine Supply
The Lymphoma Research Foundation is aware that the supply of the vital chemotherapy medicine vincristine [Oncovin] may be limited in certain areas of the country. We understand this news is very concerning to patients who receive this medicine and their…
Buildings and Landmarks Worldwide Join the Lymphoma Research Foundation to Light Red and Raise Awareness for Blood Cancer
Lymphoma Research Foundation’s Premier Light it Red for Lymphoma Initiative Expected to Reach Millions during Blood Cancer Awareness Month The Lymphoma Research Foundation (LRF) announced its annual international Light it Red for Lymphoma awareness initiative. Since 2011, the Foundation has…
LRF Chief Executive Officer Recognized as a Leader in Healthcare
Lymphoma Research Foundation Chief Executive Officer Meghan Gutierrez was recognized as a leader in healthcare by both Crain’s New York Business and PR News. Gutierrez was among 100 women listed in Crain’s Notable Women in Health Care 2019, recognizing her…
U.S. Food and Drug Administration Requests Voluntary Recall of Textured Implants Linked to Breast Implant-Associated Anaplastic Large Cell Lymphoma
The U.S. Food and Drug Administration (FDA) requested the voluntary recall from Allergan in reference to the company’s Biocell textured implants linked to breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). According to the Agency, Allergan agreed and is removing these…
U.S. Food and Drug Administration Approves Biosimilar Rituximab-pvvr (Ruxience) for CD20-positive non-Hodgkin B-cell Lymphomas and Chronic Lymphocytic Leukemia
On July 23, 2019, the U.S. Food and Drug Administration (FDA) announced it has approved the use of rituximab-pvvr (Ruxience, Pfizer), a biosimilar to rituximab (Rituxan, Genentech, Biogen) for the treatment of CD20-positive non-Hodgkin B-cell Lymphoma (NHL) and chronic lymphocytic…
Recent Study Suggests Model to Address Research Gaps and Unmet Needs in Oral Adherence for Lymphoma
Several oral agents have been proven active in the treatment of certain subtypes of non-Hodgkin lymphomas, including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), follicular lymphoma (FL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL) and Waldentröm macroglobulinemia (WM); and for…
Lymphoma Research Foundation to Honor Outstanding Lymphoma Researcher and Doctor at 2019 Annual Gala
In celebration of his incredible accomplishments as a lymphoma researcher and doctor, his years of contributions to the lymphoma community, and his support of the Lymphoma Research Foundation (LRF), LRF will honor Anas Younes, MD with its Distinguished Leadership Award…
Day of Action: Urge Congress to Support the Clinical Treatment Act
On July 10, the Lymphoma Research Foundation (LRF) is participating in a day of action in support of the Clinical Treatment Act, a bill that would provide Medicaid coverage of the routine care costs of clinical trials participation. Here is…
Foundation Announces Andrew D. Zelenetz, MD, PhD as Scientific Advisory Board Chair
The Nation’s Premier Lymphoma-Specific Research Organization Also Adds Two Experts to Industry-Leading SAB NEW YORK (July 1, 2019) – The Lymphoma Research Foundation (LRF) – the nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the…